Sign in

RIO Trial

@riotrial.bsky.social
42 followers 54 following 15 posts

Hello, RIO Trial is also now on Bluesky! The RIO study is looking at whether a new type of treatment (bNAbs) can keep HIV viral load undetectable without ART. This will involve asking all participants to stop ART for a short time. riotrial.org

PostsRepliesMedia
Reposted by RIO Trial
medRxivpreprint @medrxivpreprint.bsky.social · 06/11/2025
Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial www.medrxiv.org/content/10.1101/202…
012
RIO Trial @riotrial.bsky.social · 16/12/2025
✨ Proud moment for the RIO team! Our RIO clinical trial is featured in Nature Medicine, with our chief investigator Prof Sarah Fidler interviewed about the work. Huge thanks to our team and participants! 🔗 www.nature.com/articles/s41... #HIVResearch #ClinicalTrials #ClinicalTrials #HIV #bNAbs
nature.com
Eleven clinical trials that will shape medicine in 2026 - Nature Medicine
Nature Medicine asks leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID.
031
Reposted by RIO Trial
TAGHIVscience @taghivscience.bsky.social · 22/04/2025
Abstracts from the Spring 2025 @bhiva.bsky.social conference (open access): onlinelibrary.wiley.com/toc/14681293... #BHIVA25
onlinelibrary.wiley.com
BHIVA Spring Conference 2025, 23 April – 25 April 2025, Brighton, UK: HIV Medicine: Vol 26, No S2
Click on the title to browse this issue
023
RIO Trial @riotrial.bsky.social · 23/04/2025
i-base.info/htb/50971 Want to find out more about RIO? The brilliant @hiv-i-base.bsky.social team have published a non-technical Q&A on the recently reported results of the RIO study. Read more about it here ⬆️
i-base.info
The RIO study: Q&A about controlling HIV with bNAbs | HTB | HIV i-Base
032
RIO Trial @riotrial.bsky.social · 23/04/2025
@imperialctu.bsky.social RIO Team represented today at the @bhiva.bsky.social Spring Conference in Brighton 🤩 RIO Trial results presentation as part of the Oral Abstracts Session one - presented by RIO Chief Investigator, Prof Sarah Fidler 😊 #bhiva25 #riotrial #bnabs
063
Reposted by RIO Trial
Ming Lee @drmjlee.bsky.social · 10/04/2025
Delighted to be able to present my PhD findings of bNAb in gut tissue, alongside the primary RIO trial findings at the Keystone HIV cure symposium in Durban! #KeystoneSymposium #HIVcure2025
141
RIO Trial @riotrial.bsky.social · 10/04/2025
People who receive bNAbs respond differently, some experience delayed rebound beyond 20 weeks after one dose, and some do not rebound at all. However some people still experienced early rebound despite being screened for predicted bNAb resistance. #KeystoneSymposium #HIVcure2025
Chart showing 3 patterns of viral rebound in people in the RIO study
000
RIO Trial @riotrial.bsky.social · 10/04/2025
Dr Ming Lee, RIO trial physician @drmjlee.bsky.social presents the primary findings from RIO and his gut sub-study at the Keystone HIV cure conference in Durban, S. Africa. #KeystoneSymposium #HIVcure
Ming Lee presenting his conference talk titled 'The use of long-acting broadly neutralising antibodies to confer HIV viral control'
020
Reposted by RIO Trial
PirateThurs @piratethurs.bsky.social · 14/03/2025
La lueur d'espoir qu'il me fallait pour commencer la journée :) Je ferai peut-être partie de la dernière génération à devoir vivre avec le VIH sur le long terme. La recherche avance ✊💉🏥
011
Reposted by RIO Trial
Matthew Hodson @matthewhodson.bsky.social · 14/03/2025
Promising results from 2 HIV cure studies using antibodies. In one 20% of participants stayed off treatment without viral rebound for two years! Note: This seems far more likely to result in a workable cure for all (or many) than dangerous stem cell therapy. #CROI2025 www.aidsmap.com/news/mar-202...
aidsmap.com
Half the men in an HIV cure study stayed off treatment for nearly a year after a two-antibody shot
The day before the Conference on Retroviruses and Opportunistic Infections (CROI 2025) opened in San Francisco on Sunday, there was a community workshop on HIV cure science, at which Dr Michael Peluso...
216442
Reposted by RIO Trial
Ming Lee @drmjlee.bsky.social · 12/03/2025
As RIO and other groups have shown, bNAbs may be most promising as an immunotherapeutic intervention to enhance immun rasponsew, rather than as ART treatment. #CROI2025
051
Reposted by RIO Trial
HIV i-Base @hiv-i-base.bsky.social · 13/03/2025
Exciting early riotrial.bsky.social‬ results at #CROI2025:i-base.info/htb/50530 New #bNABs so far successful in keeping viral load undetectable in some participants off #HIVtreatment. Also the first time we’ve seen bNABs cause vaccine-like immune response. #RIOtrial #teropavimab #zinlirvimab
i-Base graphic. The main text in red and dark blue, on a light blue blue background, reads: CROI 2025. RIO study early results. Viral load remains undetectable off-ART, plus possible vaccine-like HIV cure. Below, in white on a burnt orange background, text reads, San Francisco, California. 9th to 12th March. On top of this is a faint image of the Golden Gate Bridge. In the top left corner is a URL: I hyphen base dot info. In the top right corner is a box made of blue, yellow and red blocks. White text on it reads, HTB news. 2025.
065
RIO Trial @riotrial.bsky.social · 13/03/2025
RIO is an international collaboration bringing together researchers from Rockefeller, Imperial College London, University of Oxford, and clinical sites across UK and Europe. Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
091
Reposted by RIO Trial
Imperial Clinical Trials Unit @imperialctu.bsky.social · 12/03/2025
Our ICTU Statistician Louise-Rae Cherrill is at #CROI2025 for the presentation of exciting results of the ICTU-managed @riotrial.bsky.social with promising advances in #HIVTreatment driven by immune-based therapies www.imperial.ac.uk/news/261858/...
083
RIO Trial @riotrial.bsky.social · 11/03/2025
www.youtube.com/watch?v=QnFb... RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025. Time stamps of where you can watch about the RIO Trial: Professor Fidler presents (3:05 – 6:22) Press questions (16:04 – 20:10)
youtube.com
CROI 2025 Monday (March 10) Press Conference
YouTube video by IAS-USA
023
RIO Trial @riotrial.bsky.social · 11/03/2025
Yesterday at the #CROI2025 conference in San Francesco, we were delighted to report promising results of the primary outcome of our RIO Trial , which tested long-acting immune-based therapies for HIV.
120
Reposted by RIO Trial
Imperial Medicine @imperialmed.bsky.social · 11/03/2025
New hope for #HIV treatment? Research led by @imperialcollegeldn.bsky.social unveils promising trial results showing antibody therapies could control HIV without daily medication. Read more 👇 imperial.ac.uk/news/261858/... @imperialinfect.bsky.social
imperial.ac.uk
Immune response may be harnessed to control HIV, RIO study shows  | Imperial News | Imperial College London
New antibody therapies could offer alternative to current treatments.
062
Reposted by RIO Trial
NIHR Imperial BRC @imperialbrc.bsky.social · 11/03/2025
The @riotrial.bsky.social shows that immune-based therapy can sustain viral control in multiple HIV participants, allowing them to stop daily antiretroviral medication for over a year, providing an alternative to current treatments. @imperialmed.bsky.social Full article 👇 tinyurl.com/29rsb458
imperialbrc.nihr.ac.uk
RIO Study: New antibody therapies could offer alternative to current treatments – NIHR Imperial Biomedical Research Centre
<p>Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies.</p>
011
Reposted by RIO Trial
Ming Lee @drmjlee.bsky.social · 10/03/2025
BNAbs we're safe with no serious adverse events associated with study drug or ATI. Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
121
Reposted by RIO Trial
Ming Lee @drmjlee.bsky.social · 10/03/2025
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV. Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
173
Reposted by RIO Trial
Imperial College London @imperialcollegeldn.bsky.social · 11/03/2025
Early trial results unveiled by Imperial researchers show exciting advances in HIV treatment. For the first time, immune-based treatments have managed to control the virus in patients for long periods, without the need for antiretrovirals. Find out more 🔽 www.imperial.ac.uk/news/261858/...
imperial.ac.uk
Immune response may be harnessed to control HIV, RIO study shows  | Imperial News | Imperial College London
New antibody therapies could offer alternative to current treatments.
0124
RIO Trial @riotrial.bsky.social · 11/03/2025
RIO Chief Investigator, Prof Sarah Fidler, presented the RIO primary results at CROI Conference 10 Mar 2025. Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Prof Sarah Fidler, RIO Chief Investigator, presenting the primary outcome results at the CROI Conference yesterday, 10 Mar 2025.
094
RIO Trial @riotrial.bsky.social · 11/03/2025
Hi everyone! We're very excited about joining the Bluesky community! This video explains our trial design and was coordinated by the Leadership group members: Simon Collins, Sarah Fidler, John Frater, Ming Lee and Hanna Box. #hiv #riotrial #bNAbs #CROI
vimeo.com
The RIO Trial - using a new immune-based therapy to treat HIV
This video is about a new HIV study called RIO. It uses a new immune-based therapy to treat HIV. The study is open to people who started HIV treatment soon after…
060